Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

Sionna Therapeutics, Inc.

Filed: Jun 17, 2026CIK: 0002036042
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Sionna Therapeutics held its Annual Meeting of Stockholders on June 17, 2026, electing four Class II directors to its board. This routine governance event reflects the company's leadership renewal process and establishes the board composition that will guide strategic direction through the next annual meeting.

Key Takeaways

Four Class II directors were elected: H. Edward Fleming Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D.

The meeting achieved quorum with 45,142,330 shares outstanding as of the April 21, 2026 record date

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 17, 2026
Item5.02
CategoryExecutive Change
CIK0002036042
Accession #0002036042
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board changeleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings